Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab



Pontes, Caridad, Zara, Corinne, Torrent-Farnell, Josep, Obach, Merce, Nadal, Cristina, Vella-Bonanno, Patricia, Ermisch, Michael, Simoens, Steven, Hauegen, Renata Curi, Gulbinovic, Jolanta
et al (show 13 more authors) (2020) Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 18 (1). 5 - 16.

[img] Text
Pontes et al - accepted for publication.docx - Accepted Version

Download (279kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 07 Oct 2019 13:34
Last Modified: 22 Apr 2022 16:12
DOI: 10.1007/s40258-019-00527-x
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3057345